Publication date: Dec 30, 2024
The effects of a concomitant infection of hepatitis B virus (HBV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are still debated, with a recognized major risk of HBV reactivation during immune-suppressive treatments. The aim of this study was to determine the prevalence and predictive factors of HBV reactivation in a cohort of hospitalized patients with coronavirus disease 2019 (COVID-19) and a current or past hepatitis B infection. In a monocentric retrospective observational study, we enrolled all consecutive hospital admitted patients with COVID-19 pneumonia and a positive HBV serology (N = 84) in our Infectious Diseases Unit from April 2021 to December 2023. We identified 18 (21%) HBsAg-positive/anti-HBc-positive, 41 (49%) HBsAg-negative/anti-HBc-positive/anti-HBs-positive, and 25 (30%) HBsAg-negative/anti-HBc-positive/anti-HBs-negative subjects. The overall rate of hepatitis flare was 10. 7%, without any HBsAg seroreversion, severe HBV reactivation, and/or need for new HBV antiviral therapy introduction. Systemic corticosteroid treatment for COVID-19 and baseline anti-HBsAg status were associated with this risk of HBV reactivation. In conclusion, the overall risk of hepatitis flares in hospitalized COVID-19 was reasonably low, with higher doses of corticosteroids treatment being the major risk factor for HBV reactivation, and anti-HBs-positive serological status as a protective element.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Infection |
| disease | MESH | COVID-19 |
| disease | MESH | Pneumonia |
| disease | MESH | hepatitis B |
| pathway | KEGG | Hepatitis B |
| disease | MESH | Infectious Diseases |
| drug | DRUGBANK | Hepatitis B Vaccine (Recombinant) |
| disease | MESH | hepatitis |
| disease | MESH | chronic hepatitis |
| disease | MESH | coinfection |
| disease | MESH | superinfection |
| disease | MESH | syndrome |
| disease | MESH | interstitial pneumonia |
| disease | MESH | viral infection |
| disease | MESH | abnormalities |
| disease | MESH | inflammation |
| disease | MESH | hypoxemia |
| disease | MESH | liver disease |
| disease | MESH | acute respiratory distress syndrome |
| disease | MESH | cirrhosis |
| disease | MESH | hepatocellular carcinoma |
| pathway | KEGG | Hepatocellular carcinoma |
| disease | IDO | immunodeficiency |
| disease | MESH | seroconversion |
| disease | MESH | chronic hepatitis B |